leisure time -WSS

leisure time

author：explore 2025-10-01 06:00:57 - browse：7265

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Medicare Advantage beneficiaries sue Humana over algorithm use

WSS

Christmas in the PICU brings some surprising joy

How to keep neuroscience’s past racism from being its future

Christmas in the PICU brings some surprising joy

Rare Northern Lights show in US this week: Where and how to see it

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

David Ricks of Eli Lilly: best biopharma CEO of 2023

leisure time

leisure time

focus

Walensky prepares to leave CDC — and Congress — behind

Christmas in the PICU brings some surprising joy

Trump demands the U.S. pay no more for drugs than other countries … again

David Ricks of Eli Lilly: best biopharma CEO of 2023

United colonoscopy coverage change 'may cost lives,' doctors say

Drinking water from half of US faucets contains PFAS: Study

As demand for Covid shots wanes, Moderna seeks its next success

Trump seeks lengthy delay of classified docs trial, citing upcoming election

Psychedelics group wrestles with new pharma identity

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

focus

Christmas in the PICU brings some surprising joy

Another man arrested in connection with shooting at Kansas nightclub

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

Sen. Bill Cassidy on how to lower drug prices

Readout Newsletter: The latest on Moderna, Apellis, and Merck

explore

explore

leisure time

knowledge